AGILENT TECHNOLOGIES INC. $54 (New York symbol A; Aggressive Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 333.0 million; Market cap: $18.0 billion; Price-to-sales ratio: 2.8; Dividend yield: 1.0%; TSINetwork Rating: Average; www.agilent.com) plans to break itself into two publicly traded companies. One of these businesses will keep the Agilent name and focus on testing equipment for medical-research labs.
In the parent company’s 2013 fiscal year, which ended October 31, 2013, the division that will form this new firm saw its sales rise 9.9%, to $3.9 billion from $3.5 billion in fiscal 2012. That’s mainly due to strong demand from pharmaceutical makers, and rising sales of gear for testing food safety in China and other developing countries. This company will pay a dividend comparable to Agilent’s current 1.0% yield.
The second company will make testing systems for improving electronics, such as cellphones and computer equipment. Its fiscal 2013 revenue fell 12.9%, to $2.9 billion from $3.3 billion. That’s partly because U.S. budget cuts hurt demand from aerospace and defence clients. However, new testing systems for wireless networks should boost this firm’s revenue in fiscal 2014. This second firm will not pay a dividend, at least initially.
Overall, Agilent’s fiscal 2013 revenue fell 1.1% from a year earlier, which pushed down its earnings by 9.5%, to $995 million from $1.1 billion. Due to fewer shares outstanding, earnings per share fell 7.7%, to $2.88 from $3.12. The company spent $704 million (or 10.4% of its revenue) on research, up 5.4% from $668 million (or 9.7% of revenue).
Agilent will hand out shares in the electronics-testing business to its current investors, who will not be liable for capital gains taxes on their new shares until they sell them. Shareholders and regulators must approve the breakup, but the company aims to complete it in November 2014.
Demand for electronics-testing gear is highly cyclical, so spinning off this business will unlock some of the value of Agilent’s faster-growing medical equipment operations. Moreover, the stock trades at a still attractive 17.0 times its projected 2014 earnings of $3.17 a share.
Agilent is still a buy.